

## Notice of References Cited

Application/Control No.

09/775,479

Applicant(s)/Patent Under

Reexamination  
LECLERC ET AL.

Examiner

David A Lambertson

Art Unit

1636

Page 1 of 1

### U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

**BEST AVAILABLE COPY**

### FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

### NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages
	U	Fareh et al. Feasability, safety and dosimetry of intramural administration of 32P-oligonucleotide-mediated beta-particle delivery to prevent restinosis. January 1, 2001. Cardiovascular Radiation Medicine 2(1): 51.
	V	O'Sullivan et al. Gene therapy for coronary restenosis: Is the enthusiasm justified? November 2001. Heart 86(1): 491-493.
	W	
	X	

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)

Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.